1-866-598-7166

A Study of NIS793 Alone or in Combination with PDR001 in Patients with Advanced Solid Tumours

Trial ID: NCT02947165


Background:
This trial features two experimental immunotherapy drugs, NIS793 and PDR001. These drugs work by enhancing or changing the way that the immune system responds to cancerous cells.

PDR001 targets a molecule called PD-1, similar to an already approved immunotherapy called pembrolizumab (Keytruda®). This allows the immune system to more effectively target and destroy cancer cells.

Meanwhile, NIS793 works by blocking a new potential cancer-target called TGFβ. Research has shown that the loss of this factor may prevent cancerous cells from growing, dividing, and spreading.

The Trial:
Patients enrolling on this study will be randomly assigned to one of two groups:

  1. NIS793 Alone
  2. NIS793 + PDR001

This study is specifically designed for patients with advanced kidney cancer who have completed standard therapy and whose cancer has continued to grow despite treatment.

Basic Eligibility:

  • All subtypes eligible
  • Cancer has spread or cannot be removed by surgery
  • Must be able and willing to undergo a tumour biopsy

Additional eligibility criteria will apply. Please speak to your doctor.

 

Find out more about this study
Hospital / Cancer CentrePrincipal InvestigatorLocationTrial Status
Hospital / Cancer CentreNovartis Investigative Site Principal Investigator LocationToronto, ON Trial StatusRecruiting
Do NOT follow this link or you will be banned from the site!